1. A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE‐CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL). (June 2017) Authors: Locatelli, F.; Mauz‐Koerholz, C.; Neville, K.; Llort, A.; Beishuizen, A.; Daw, S.; Pillon, M.; Aladjidi, N.; Klingebiel, T.; Landman‐Parker, J.; Medina‐Sanson, A.; August, K.; Huebner, D.; Sachs, J.; Hoffman, K.; Kinley, J.; Song, S.; Song, G.; Zhang, S.; Gore, L. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors. (December 2016) Authors: Razak, A.; Gore, L.; Britten, C.D.; Miller, W.H.; Uy, G.L.; Nichols, G.; Middleton, S.; Blotner, S.; Zhi, J.; Jukofsky, L.; Pierceall, W.; Higgins, B.; Chen, L.C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION. (23rd June 2022) Authors: Gore, L.; Loh, M.; Pui, C.-H.; Matloub, Y.; Hanley, M. J.; Du, J.; Hennessy, M.; Granier, M.; Biondi, A.; Silverman, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1644 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗